{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Showing 1 - 3 of 3 results
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03589833: Phase 4 Interventional Completed Arthritis, Rheumatoid
(2019)
Source URL:
First approved in 2013
Source:
PAMO Kill Natural by GeoRim Pharmaceutical
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2009)
Source URL:
First approved in 2009
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE